More than 15 years have passed since the identification, through linkage, of 'first-wave' susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These genes have strong frequency-penetrance profiles, such that the associated clinical utility probably remains relevant regardless of the context of ascertainment. 'Second-wave' genes, not tractable by linkage, were subsequently identified by mutation screening of candidate genes (PALB2, ATM, CHEK2, BRIP1, RAD51C and RAD51D). Their innately weaker frequency-penetrance profiles have rendered delineation of cancer associations, risks and variant pathogenicity challenging, thereby compromising their clinical application. Early germline exome-sequencing endeavors for common cancers did not yield the long-anticipated slew of 'next-wave' genes but instead implied a highly polygenic genomic architecture requiring much larger experiments to make any substantive inroads into gene discovery. As such, the 'genetic economics' of frequency penetrance clearly indicates that focused identification of carriers of first-wave-gene mutations is most impactful for cancer control. With screening, prevention and early detection at the forefront of the cancer management agenda, we propose that the time is nigh for the initiation of national population-testing programs to identify carriers of first-wave gene mutation. To fully deliver a precision prevention program, long-term, large-scale mutation studies that capture longitudinal clinical data and serial biosamples are required.
T he past 30 years has witnessed substantial improvements in the management of cancer, including striking successes in the treatment of testicular and pediatric cancers, and many hematological malignancies. Despite these advances, because of the high proportion of patients presenting with late-stage disease, mortality rates have remained disappointingly poor for many common cancers, such as those of the colorectum and pancreas 1 . The initial optimism that precision oncology would address the poor outcomes for metastatic cancer has been tempered by understanding of the challenges associated with tumor heterogeneity, tumor evolution and the emergence of resistance mutations 2 . Hence, the precision oncology vision is unlikely to be a universal panacea in decreasing the bulk cancerrelated mortality associated with most common solid tumors 3 . This recognition has in part driven renewed interest in exploring opportunities for optimizing early detection of cancer through screening and prevention programs. Any such strategy is likely a priori to have more impact if targeted to those at the highest risk of developing cancer. This premise has been a central philosophy in the application of genetic testing for mutations in the cancer susceptibility genes (CSGs) that is now commonplace in family cancer clinics. Because most cancers have a substantial heritable component 4 , there is now interest in the potential of genetic risk profiling to deliver personalized prevention programs to the wider population 5 . This prospect has been made possible as a result of the phenomenal progress in the identification of CSGs and risk variants.
Here, we discuss current understanding of the genetic architecture of cancer susceptibility and current and future opportunities, and we consider the case for implementing large-scale genetic testing.
First-wave and second-wave cancer susceptibility genes
For most common cancers, first-degree relatives of patients with cancer have a two-to threefold-higher risk of the same cancer.
Notable exceptions are chronic lymphocytic leukemia and thyroid and testicular cancers, for which the risks are four-to eightfold higher 6 . The genetic architecture underscoring these familial risks is now known to reflect a range of alleles with varying frequencies and effect sizes 7 . Genetic linkage and positional cloning studies of multicase families in the 1990s delivered the first tranche of CSGs for nonsyndromic clusters of common cancers, most notably for breast and ovarian cancers (BRCA1 and BRCA2), colorectal cancer (mismatch repair (MMR) genes MLH1 and MSH2) and melanoma (CDKN2A) [8] [9] [10] [11] [12] . However, subsequent linkage analyses of the sizeable numbers of residual 'unexplained' large pedigrees failed to yield 'BRCA3' or equivalent, thus leading to a gradual acceptance that for these common cancers, no further CSGs with first-wave frequency-risk profiles existed 13, 14 . Alternative experimental approaches were required, and focus was moved to candidate-gene experiments informed by the pathways identified by the first-wave CSGs. During the 2000s, mutational screening of genes involved in DNA repair led to the identification of a second tranche of CSGs, including MUTYH, PALB2, CHEK2, BRIP1, ATM, RAD51C and RAD51D 7, [15] [16] [17] [18] [19] [20] [21] [22] . Given the simplistic biological rationale and the limited size of experiments feasible with available low-throughput technologies, the yield of second-wave CSGs from these early gene-screening endeavors was, in retrospect, strikingly rich 23 .
Clinical characterization of cancer susceptibility genes
Despite more than 20 years of study, the estimates of cancer risk for the first-wave genes remain relatively imprecise with considerable variation between analyses, and the association of additional new cancers is regularly reported (and disputed). Plotting of frequencyrisk profiles demonstrates that both BRCA1 and BRCA2 lie well above the linear function obeyed by second-wave and other breast cancer genetic-susceptibility variants; MLH1 and MSH2 perform similarly against colorectal susceptibility factors, albeit with less dramatic delineation (Fig. 1) . It is therefore unsurprising that characterization of the second-wave genes with much weaker frequencyrisk profiles has proven highly problematic, despite the generation of high volumes of data over the past decade through both research and clinical high-throughput sequencing of cancer gene panels.
The first, seemingly basic, challenge has been establishing which cancers are truly associated with pathogenic mutations in these newer second-wave genes. Uncertainty persists as to whether reported 'breast cancer susceptibility genes' such as BARD1, RAD50, NBN (also known as NBS1) and RECQL are actually associated with breast cancer risk [24] [25] [26] [27] [28] . BRIP1, originally reported as a CSG for breast cancer, was subsequently shown through recent large-scale analyses to influence only ovarian cancer risk 20, [29] [30] [31] . Likewise, there are multiple conflicting reports as to whether the ovarian cancer susceptibility genes RAD51C and RAD51D also confer a risk of breast cancer 16, 17, [32] [33] [34] [35] . More tangentially, the purported association of mosaic mutations in PPM1D as a cause of susceptibility to breast and ovarian cancer seems instead simply to represent the confounding artifact of chemotherapy [36] [37] [38] [39] . The second challenge is establishing the magnitude of cancer risk (also known as penetrance) conferred by CSG mutations. Initial studies suggested that PALB2 mutations confer only a modest twofold risk of breast cancer 18 . Subsequent (i) assembly of the world's largest set of PALB2-mutation-positive families with adjustment for ascertainment and (ii) large case-control analyses of unselected breast cancer cases both support that the true penetrance of PALB2 mutations for breast cancer are of a magnitude to warrant management equivalent to that for BRCA2. Widespread rollout of clinical testing for PALB2 was significantly delayed on account of clinical concern arising from this disparity in risk estimates 40, 41 . For ATM, epidemiological and pan-mutation analyses support intermediate penetrance with respect to breast cancer risk (relative risks of 2-3); however, again there are reports of specific missense ATM mutations having BRCA-equivalent risks 19, 40, [42] [43] [44] . For CHEK2, the breast cancer risks for the relatively frequent 1100delC mutation are well explored and reproducible (relative risk, 2-3), but for other mutations and cancer associations of CHEK2, the data are conflicting 21, [45] [46] [47] [48] [49] [50] . Such observations, in part, reflect the disparity in estimates of mutation penetrance differing between analyses of heavily laden families and those of the general population, thus reflecting the influence of modifiers and environment. Only through very large unbiased studies of population-based data will the true associations and risks for variants in these second-wave genes be ratified.
The third challenge lies in establishing which of the many variants in these genes are truly 'pathogenic' . To date, there has been poor correlation with clinical pathogenicity for most functional assays and in silico predictions (largely derived from interspecies conservation and physiochemical amino acid similarity) 51 . Accordingly, establishing pathogenicity for rare variants in firstwave genes has been challenging and has largely relied on comparison of allele frequencies incorporating tumor characteristics, family phenotype and segregation. However, for second-wave genes, except for founder mutations, such analyses are almost impossible, owing to very low frequencies of individual variants and/or modest risks. Accordingly, there have been minimal inroads in ascribing pathogenicity to anything other than nonsense and frameshift mutations in second-wave genes, aside from occasional missense variants found in children with the rare biallelic phenotype (e.g., ataxia telangiectasia) 19 . Assessing pathogenicity for individual nonfounder variants in second-wave genes will probably be feasible only if robust functional assays can be developed (which correlate perfectly with clinical pathogenicity). Early data from CRISPR saturation editing of BRCA1 by multiplex homology-directed repair are heralding tentative enthusiasm regarding meeting this long-sought goal 52, 53 . Clearly, association of a gene with cancer, penetrance and variant 'pathogenicity' are interdependent within the analysis. The 'working' clinical estimates for these parameters have often been derived from overlapping analyses of the same underlying datasets, which are almost invariably distorted by ascertainment bias and limited by power, and are frequently subject to population stratification.
Clinical testing for cancer susceptibility
The increasing affordability and throughput of high-throughput sequencing coupled with relaxation of gene patents has led to the effective 'deregulation' of clinical testing of CSGs. For a given cancer type, the 'clinical panel' typically includes (i) relevant first-wave and second wave genes; (ii) selected genes to date characterized only within extremely rare, highly distinctive pleomorphic cancer syndromes, such as PTEN, TP53, CDH1 and STK11; and often (iii) additional genes with dubious or no evidence for association 54 . For the second-wave genes of (seemingly) higher penetrance, mutations have proven strikingly infrequent, as exemplified by the yield on testing of PALB2 in familial breast cancer or RAD51C and RAD51D in familial ovarian cancer 16, 17, 28, 32, 55 . Furthermore, the conflicting published data regarding basic disease associations and penetrance have unsurprisingly resulted in disparities in clinical management for carriers of mutations in these genes (including individuals from the same family managed in different treatment centers). For genes with intermediate penetrance, such as CHEK2, effective management paradigms for families remain unclear 56 . In contrast to the case of BRCA1 detection, when a CHEK2 mutation is detected in a breast cancer proband, cascade testing in the family does not neatly place unaffected family members into dichotomized categories of high and low risk.
Furthermore, the complexity deepens as genetic testing is extended outside the context of familial disease, into unselected incident cancer cases or indeed the general population. The inherently stronger frequency-penetrance function for first-wave genes has made possible both large studies of mutation-positive families and analyses in large unselected cancer cohorts [57] [58] [59] [60] [61] [62] . Triangulation of these data has suggested a 'true' (or average) penetrance sufficiently high to suggest that interventions for screening and prevention are likely to remain relevant regardless of ascertainment 60, 61 . For most second-wave genes, the true penetrance is uncertain: ascertainment outside of the familial context thus further amplifies uncertainties regarding the efficacy of and justification for available clinical interventions.
The 'rare syndromic' genes such as TP53, STK11 and CDH1 also pose challenges in testing outside of a classical familial context. A case has been made for testing unselected cancer cases on account of concern that these conditions may be underdiagnosed, especially because mutations can have pleomorphic effects and can arise de novo. However, there are limited data on cancer risks outside of the families ascertained on the basis of classic phenotype. Higherthan-predicted mutational frequencies in control data suggest that the disease risks quoted in classic families grossly exceed those applicable to mutation carriers ascertained from the general population [63] [64] [65] [66] [67] . Until such risks are better established, extending testing for these genes beyond 'classical' or familial contexts may lead to interminable challenges in patient management. The risk-benefit tradeoff for prophylactic gastrectomy would be highly uncertain if a pathogenic CDH1 variant were found in an unaffected individual or isolated breast cancer case without relevant family history.
For many clinicians, the initial enthusiasm for offering testing of a broader palette of genes has been tempered by such uncertainties as well as the low detection rates. Some would go so far as to argue that the 'additional content' on panels beyond first-wave genes has only inflated the costs of mainstreaming genetic testing while generating a spiraling industry in the interpretation and overmanagement of variants of uncertain significance. Moreover, use of inflated estimates of cancer risk may unduly elevate patient anxiety and divert healthcare resources toward screening and preventive surgery of questionable benefit to individual patients, let alone justification in the context of public health 68 .
Genome-wide association studies ten years on
Early proponents of the common variant-common disease hypothesis had envisaged that genome-wide association studies (GWAS) might deliver a tractable 'set' of common variants for each tumor type, thus capturing a large proportion of the heritable risk. The field of public health genomics arose in anticipation of implementing such information to stratify the population into neat tranches of risk for programs of screening and prevention 69 . In 2007, the longawaited first-wave results from GWAS for the common cancers were reported. The top associations were striking for their modest effect sizes, with a relative risk of only 1.26 for the top breast cancer risk locus (intron 2 of FGFR2) 70, 71 . Subsequently, larger GWAS identified respectable yields of additional hits but confirmed the portentous power calculations of the early GWAS, namely that each tumor type has an underlying genomic architecture comprising several hundred loci with progressively more modest contributions 69, [72] [73] [74] [75] . Initiatives such as the Breast Cancer Association Consortium (BCAC) have delivered experiments of increasing magnitude, each time adding to the proportion of familial relative risk (FRR) explained [76] [77] [78] [79] [80] [81] . The most recent Oncoarray experiment from BCAC, involving some 140,000 cases and a similar number of controls, was sufficiently powered to show 18% of the FRR for breast cancer being attributable to 140 risk single-nucleotide polymorphisms (SNPs). Although statistical modeling indicates that ~40% of the FRR is likely to be enshrined in common variation, projections suggest that sample sizes in excess of 300,000 will be required to explain 80% of this component of the heritable risk of breast and colorectal cancer 78 . Although large biobanks exist for some cancers, for many tumors, assembling the magnitude of samples required to harvest a substantial proportion of the FRR will probably prove prohibitive. Even though issues of power may challenge the clinical application of GWAS, GWAS has nonetheless provided a wealth of insights into cancer biology, which may in due course offer patient benefits 82 .
Rationalizing strategies informed by genomic architecture
As we reach the decade mark from the rollout of both GWAS and high-throughput screening, it is imperative that 'real-life genetic testing experiments' from the clinic be overlaid onto candid insights from research endeavors.
The palette of long-awaited second-wave genes available over the past few years in practice had markedly limited effects on clinical care. This is a direct function of the risk-penetrance profiles of these genes. Power analyses from initial exome-sequencing endeavors in common cancers suggest overwhelmingly that the next-wave susceptibility genes/rare alleles will have equivalent or more modest risk-penetrance profiles than the second-wave genes. Major inroads toward identification of this next wave of susceptibility genes/ alleles will be achievable only through exome/genome-sequencing studies using sample sizes that are scales of magnitude greater than previously used (e.g., > 50,000 cases and 50,000 controls) 83, 84 . Furthermore, characterizing cancer association, penetrance and variant pathogenicity for any next-wave genes will be commensurately even more challenging than for second-wave genes.
Therefore, owing to the immoveable truth of risk-penetrance function, clinical utility from germline genetic testing for cancer susceptibility has been, and will be for the foreseeable future, best effected through focus of resources on identification of carriers of mutations in the stalwart first-wave genes, BRCA1, BRCA2, MLH1 and MSH2 (Fig. 1) . Clinical-research rhetoric and priorities should focus therefore on leveraging full value from the first-wave genes, by (i) expanding identification of mutation carriers; (ii) long-term statistical genetic epidemiologic studies to better establish association, penetrance and variant pathogenicity; and (iii) longitudinal biosampling to better understand cellular biology, precancer states and tumorigenesis (Box 1).
implementing large-scale population-level genetic testing
The threshold for testing BRCA1/BRCA2 and MMR genes on the basis of family history has been progressively lowered over the past two decades, and ascertainment of families through 'mainstream' testing at cancer diagnosis is becoming established. However, even in countries with well-developed genetics services, fewer than 10% of prevalent BRCA and MMR mutation carriers have been identified 85 . Even with expansion of testing in oncology, ascertainment of 'the totality' of prevalent BRCA1/BRCA2 and MMR mutations would take many decades under the current models 85 . Testing for BRCA1/BRCA2 founder mutations has been well demonstrated to be economically and clinically effective: systematic rollout of founder testing in relevant subpopulations is long overdue [85] [86] [87] [88] [89] [90] . Furthermore, there is increasing clinical impetus and healtheconomic evidence in support of offering testing to the general population for mutations in BRCA1/BRCA2 and MMR genes, even given the requirement for more expansive analysis of the genes and lower mutation detection rates than in founder mutation population programs 86, 91 . For each given cancer, the predictive value of the 'testable SNP set' feasibly tractable by GWAS is also now becoming clear [92] [93] [94] [95] [96] [97] [98] [99] [100] , and 'jump-time' is nigh for rollout of trials of population SNP cancer risk profiling. Although not quite the catholicon initially anticipated, SNP risk profiling applied at the population level can offer valuable risk discrimination for certain tumors, particular when combined with a predictive set of nongenetic risk factors 101 . Furthermore, intermediate-penetrance susceptibility genes such as ATM, CHEK2 and BRIP1, despite having equivocal value in the familial cancer clinic and being rare, add value in the context of population genetic risk stratification 102, 103 . The value proposition of genomic risk profiling is not solely based on the discriminatory performance of the 'prediction tool' but is heavily predicated on factors such as disease frequency, disease mortality, disease natural history, biomarkers of tumor behavior and interventions available for screening and prevention (Fig.  2) . Breast, ovarian and colorectal cancers would seem to emerge as prime candidates for population risk profiling. Each cancer is common and/or has a significant burden of mortality. For each, there is a plausible tripartite prediction tool (comprising common variants, nongenetic factors and high/intermediate-penetrance susceptibility genes). For each, there are effective options for intervention: screening, chemoprophylaxis and surgery. Modeling, health-economic and pilot implementation studies for population genetic testing for these cancers are urgently required.
Conclusion
The emergence of transformative new technologies has fostered great expectations for gene discovery and delivery of new paradigms in genomic risk prediction for cancer. High-throughput screening has offered clinicians and researchers the promise of new clinicready CSGs with which to 'diagnose' previously unrecognized families with breast and colorectal cancer. Instead, the high-throughput screening experiments performed to date have shown the genomic architecture of these common cancers to be much more complex than originally anticipated.
Box 1 | Priority research themes for BRCA and MMR: reaping new value from old hitters
A precancer atlas to deliver insights into premalignant-cell biology, develop biomarkers for surveillance and evolve precision chemoprevention. Large-scale serial collection of multiple biosamples from mutation carriers, development of engineered models, application of single-cell technologies, multi-omic analyses, studies of the microenvironment and immunological approaches will accelerate understanding of precancer biology and tumorigenesis, as has been well described by Lipman and colleagues 108 . This understanding will in turn facilitate discovery of biomarkers and development of chemotherapeutic agents, chemopreventive agents and vaccines. Animal experiments of rank-ligand inhibition have shown potential for chemoprevention in BRCA carriers; clinical trials are in early rollout 109, 110 . Chemoprevention for colorectal cancer is an underexploited area: exposition of the molecular basis for the protective effect of aspirin may yield additional benefit beyond applications for MMR carriers and colorectal cancer. The predictable expressed epitopes of the MMR-deficient hypermutated tumors offer a promising model for immunological modulation and cancer vaccines 111 . The distinctive hypermutated profile of MMR-deficient tumors, alongside their high a priori cancer risks, surely renders MMR-mutation carriers well suited for early prospective studies of cDNA monitoring for colorectal cancer. ; (ii) risk-modifying SNPs for BRCA1 and BRCA2 can be used to differentiate mutation carriers into clinically meaningful strata of risk 105, 112 ; (iii) regions in both BRCA1 and BRCA2 have been delineated for which the comparative risks of breast and ovarian cancer differ significantly (BCCRs and OCCR); and (iv) for BRCA1, mutation-specific risks have emerged, which are clearly distinct from the generally deployed 'pan-mutation' risks [113] [114] [115] . Larger datasets that are controlled for ascertainment, fully typed for genetic factors and well characterized for nongenetic factors are urgently required to better model risk. These datasets would also enable more rigorous testing for nonmultiplicative interactions among risk factors. Moreover, clinician and patient decision-support tools that are well designed to present and translate these complex data on clinical risk (along with its bounds of uncertainty) are also needed.
Variant interpretation paradigms designed for cancer susceptibility genetics. Consistency in variant interpretation has been greatly advanced by ClinVar, which is emerging as the de facto centralized community variant-classification repository, and by American College of Medical Genetics and Genomics (ACMG) standardization of classification criteria 116, 117 . However, the ACMG framework is best suited to rare dysmorphic syndromes: evolution of dedicated approaches for CSGs is in process. Each CSG is different in terms of both biology and mutational patterns. As is currently being enacted by ENIGMA, InSIGHT and ClinGen expert groups, a combination of genespecific expertise alongside universally consistent frameworks is required. Starting with first-wave genes, such self-organizing activities offer the prospect of consistent, systematic processing of genetic data, collaborative international deposition and comprehensive annotation. Furthermore, major advances in the field are imminent, from development of massively highthroughput functional assays, such as saturation editing of genomic BRCA1 regions by multiplex homology-directed repair and splicing assays such as multiplexed functional assay of splicing using Sort-seq (MFASS) 52, 118 .
Box 2 | Research 'platforms' for studying BRCA and MMR genes
To establish and expand biological, epidemiological and clinical trials, platforms will require (i) coordinated, systematic assembly of large cohorts of mutation carriers, (ii) flexible and considered structures of consent and (iii) long-term, sustainable funding. The platforms should include the following:
Prospective cohorts to advance studies of penetrance and association (observational epidemiology). These studies should include longitudinal data linkage of germline genetic status to cancer occurrence, treatment and outcomes, including in addition information on screening, preventive surgery and details of ascertainment.
Longitudinal acquisition of biological samples ('precancer' and cancer atlases). Biomarker discovery and insights into precancer biology will be accelerated through large-scale serial collection of multiple biosamples (e.g., blood, urine, saliva, normal colonic tissue, exhaled gases, lavage from breast ducts, peritoneal lavage, polyps, carcinomas in situ and tumor tissue) from mutation carriers.
National infrastructure for clinical trials in CSG-mutation carriers. This infrastructure should include comprehensive national networks of traceable mutation carriers consented for contact, with which to enact responsive, well-powered trials of screening or chemoprophylaxis.
Testing dozens of genes with vanishingly low mutational frequency, poorly characterized risk and/or questionable association with disease has delivered limited gains. Instead, guided by basic frequency-penetrance 'economics' , we should reembrace the firstwave genes and focus our efforts on identifying as many mutation carriers as possible. We should denounce the procrastination of awaiting additional future 'new genes' to 'add value' to the population-screening proposition. The time is ripe for large-scale implementation studies of population BRCA and MMR gene testing (potentially in tripartite combination with risk profiling based on common genetic and nongenetic factors). In parallel, we need to shift now to a delivery mode based on proper 'individualized' precision prediction and management for mutation carriers. To deliver individualized risk management and precision prevention, there is an urgent need for clinical tools integrating existing data on gene-, location-and individual mutation-specific risk; common genetic and nongenetic modifiers; family history; and the context of ascertainment 100, 104, 105 . Although great progress has already been made on the characterization and clinical applications of these genes, to fully deliver their value in cancer prevention, substantial and sustained investment in research platforms will be required to deliver the necessary longterm epidemiological, biological and clinical studies (Box 2). 
